- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
March
7 Mar 2023 - Notice of General Meeting/Proxy Form
February
23 Feb 2023 - Appendix 4D and Half Year Financial Report
13 Feb 2023 - Change of Director's Interest Notice- Alan Yamashita
13 Feb 2023 - Change of Director's Interest Notice - Thian Chew
13 Feb 2023 - Notification of cessation of securities - IVX
8 Feb 2023 - Expansion of Territory Rights to USA, Canada and Hong Kong
January
30 Jan 2023 - Activities Report and Appendix 4C
20 Jan 2023 - Notification regarding unquoted securities - IVX
November
17 Nov 2022 - Change of Director's Interest Notice - Thian Chew
17 Nov 2022 - Notification regarding unquoted securities - IVX
17 Nov 2022 - New Constitution
17 Nov 2022 - Results of Annual General Meeting
17 Nov 2022 - AGM Presentation
October
27 Oct 2022 - Invion Conference Presentation
26 Oct 2022 - Photosoft Effective Against Superbugs and Other Pathogens
24 Oct 2022 - Photosoft shows activity against Dengue in Preliminary Assay
18 Oct 2022 - Invion Conference Presentation
17 Oct 2022 - Activities Report and Appendix 4C
14 Oct 2022 - Notice of Annual General Meeting
10 Oct 2022 - Change in substantial holding
September
27 Sep 2022 - Hudson Institute to Present Photosoft at Combio2022
21 Sep 2022 - Change of Director's Interest Notice - Alistair Bennallack
21 Sep 2022 - Section 708A Cleansing Statement
21 Sep 2022 - Application for quotation of securities - IVX
15 Sep 2022 - INV043 Effective Against Anal Cancer SCC In Vitro
13 Sep 2022 - Change of Director's Interest Notice - Alistair Bennallack
13 Sep 2022 - Change of Director's Interest Notice- Alan Yamashita
13 Sep 2022 - Change of Director's Interest Notice- Robert Merriel
13 Sep 2022 - Change of Director's Interest Notice - Thian Chew
13 Sep 2022 - Notification regarding unquoted securities - IVX
13 Sep 2022 - Response to ASX Aware Query
8 Sep 2022 - Photosoft Shows Activity Against Zika Virus
August
18 Aug 2022 - Appendix 4G and Corporate Governance Statement
18 Aug 2022 - Appendix 4E and Annual Report
July
21 Jul 2022 - Activities Report and Appendix 4C
June
8 Jun 2022 - International Patent to Extend IP Protection for Photosoft
May
30 May 2022 - INV043 Significantly Improved Checkpoint Inhibitor Therapy
April
20 Apr 2022 - Activities Report and Appendix 4C
March
29 Mar 2022 - Results of General Meeting
21 Mar 2022 - Change of Director's Interest Notice - Alistair Bennallack
21 Mar 2022 - Change of Director's Interest Notice- Alan Yamashita
21 Mar 2022 - Change of Director's Interest Notice- Robert Merriel
21 Mar 2022 - Change of Director's Interest Notice- Thian Chew
21 Mar 2022 - Notification regarding unquoted securities - IVX
February
25 Feb 2022 - Notice of General Meeting/Proxy Form
22 Feb 2022 - Appendix 4D and Half Year Financial Report
03 Feb 2022 - Investor Presentation
02 Feb 2022 - Application for quotation of securities - IVX
January
20 Jan 2022 - Activities Report and Appendix 4C
December
22 Dec 2021 - Change in substantial holding
16 Dec 2021 - Top 20 Listed Option Holders
16 Dec 2021 - Appendix 2A
13 Dec 2021 - Application for quotation of securities - IVX
8 Dec 2021 - Change in substantial holding
7 Dec 2021 - Change of Director's Interest Notice - Alistair Bennallack
7 Dec 2021 - Change of Director's Interest Notice- Alan Yamashita
7 Dec 2021 - Change of Director's Interest Notice- Robert Merriel
7 Dec 2021 - Change of Director's Interest Notice- Thian Chew
7 Dec 2021 - Notification regarding unquoted securities - IVX
November
25 Nov 2021 - Proposed issue of securities - IVX
25 Nov 2021 - Supplementary Prospectus
24 Nov 2021 - Release of securities from escrow
23 Nov 2021 - Cancel - Proposed issue of securities - IVX
23 Nov 2021 - Cancellation of Options
23 Nov 2021 - Proposed issue of securities - IVX
23 Nov 2021 - Proposed issue of securities - IVX
23 Nov 2021 - Prospectus
22 Nov 2021 - Notification regarding unquoted securities - IVX
22 Nov 2021 - Share Purchase Plan Offer Booklet & Application Form
22 Nov 2021 - Section 708A Cleansing Statement
22 Nov 2021 - Application for quotation of securities - IVX
16 Nov 2021 - Proposed issue of securities - IVX
16 Nov 2021 - Proposed issue of securities - IVX
16 Nov 2021 - Proposed issue of securities - IVX
16 Nov 2021 - Capital Raising and expansion of Photosoft Territory
12 Nov 2021 - Trading Halt
9 Nov 2021 - Results of Annual General Meeting
9 Nov 2021 - AGM Presentation
1 Nov 2021 - Jobkeeper Payments Notice
October
29 Oct 2021 - Appointment of Company Secretary
29 Oct 2021 - Further Information on Proof of Concept Pilot Study
28 Oct 2021 - Complete Regression of TNBC Tumours and Protective Immunity
21 Oct 2021 - Activities Report and Appendix 4C
8 Oct 2021 - Grant of ASX Waiver
8 Oct 2021 - Notice of Annual General Meeting/Proxy Form
8 Oct 2021 - Change in substantial holding
6 Oct 2021 - Change of Director's Interest Notice- Robert Merriel
6 Oct 2021 - Section 708A Cleansing Statement
6 Oct 2021 - Change of Director's Interest Notice - Alistair Bennallack
6 Oct 2021 - Application for quotation of securities - IVX
4 Oct 2021 - Section 708A Cleansing Statement
4 Oct 2021 - Change of Director's Interest Notice- Robert Merriel
4 Oct 2021 - Application for quotation of securities - IVX
4 Oct 2021 - Application for quotation of securities - IVX
4 Oct 2021 - Change of Director's Interest Notice - Alistair Bennallack
4 Oct 2021 - Notification regarding unquoted securities - IVX
4 Oct 2021 - Change of Director's Interest Notice- Thian Chew
4 Oct 2021 - Notification regarding unquoted securities - IVX
September
23 Sep 2021 - Results of General Meeting
17 Sep 2021 - Change of Director's Interest Notice- Alan Yamashita
17 Sep 2021 - Change of Director's Interest Notice- Robert Merriel
17 Sep 2021 - Change of Director's Interest Notice- Thian Chew
17 Sep 2021 - Notification regarding unquoted securities - IVX
August
23 August 2021 - Notice of General Meeting
5 August 2021 - Securities Trading Policy
5 August 2021 - Appendix 4G and Corporate Governance Statement
5 August 2021 - Appendix 4E and Annual Report
July
22 July 2021 - Activities Report and Appendix 4C
9 July 2021 - CEO Contract
June
18 June 2021 - Change of Director's Interest Notice- Rob Merriel
11 June 2021 - Change of Director's Interest Notice- Alan Yamashita
11 June 2021 - Change of Director's Interest Notice- Rob Merriel
11 June 2021 - Change of Director's Interest Notice- Thian Chew
11 June 2021 - Notification regarding unquoted securities - IVX
9 June 2021 - Change of Director's Interest Notice- Rob Merriel
9 June 2021 - Section 708A Cleansing Statement opens new window
9 June 2021 - Application for quotation of securities - IVX
4 June 2021 - Change of Director's Interest Notice - Alistair Bennallack
2 June 2021 - Capital Raising & co-development for Photosoft Technology
May
31 May - Trading Halt
27 May 2021 - Release of securities from escrow
25 May 2021 - Initial Proof-of-Concept results show INV043 to be effective
April
27 April 2021 - Selection of New API (INV-043) and Next Steps in R&D Program
23 April 2021- Activities Report and Appendix 4C
13 April 2021 - Change of Director's Interest Notice- Rob Merriel
13 April 2021 - Section 708A Cleansing Statement
13 April 2021 - Appendix 2A
7 April 2021 - Change of Director's Interest Notice- Alan Yamashita
7 April 2021 - Change of Director's Interest Notice- Rob Merriel
7 April 2021 - Change of Director's Interest Notice- Thian Chew
7 April 2021 - Appendix 3G
February
25 February 2021 - App 4D and Financial Report for half year to 31 Dec 2020
22 February 2021 - Release of securities from escrow
January
21 January 2021 - Activities Report and Appendix 4C
18 January 2021 - Becoming a substantial holder
18 January 2021 - Change in substantial holdings
12 January 2021 - Change of Auditors
December
24 December 2020 - Statement 708A Cleansing Statement
23 December 2020 - Change of Director's Interest Notice - Rob Merriel
23 December 2020 - Appendix 2A
15 December 2020 - Change of Director's Interest Notice - Thian Chew
15 December 2020 - Change of Director's Interest Notice - Rob Merriel
15 December 2020 - Change of Director's Interest Notice - Alan Yamashita
15 December 2020 - Appendix 3G
4 December 2020 - Distribution of shares by substantial shareholder
4 December 2020 - Lapse of unlisted options
November
23 November 2020 - Change of Director's Interest Notice - correction
5 November 2020 - Final Director's Interest Notice - Craig Newton
5 November 2020 - Lapse of unlisted options
5 November 2020 - Change of Director's Interest Notice - Craig Newton
5 November 2020 - Appendix 3G
5 November 2020 - Cleansing Notice and Appendix 2A
October
28 October 2020 - Change of Director's Interest Notice - Thian Chew
28 October 2020 - Change of Director's Interest Notice - Alan Yamashita
28 October 2020 - Appendix 3G
28 October 2020 - Appendix 3G
28 October 2020 - Initial Director's Interest Notice
26 October 2020 - Activities Report and Appendix 4C
26 October 2020 - Director Appointment
21 October 2020 - Results of Annual General Meeting
21 October 2020 - AGM Presentation
September
21 September 2020 - Grant of ASX Waiver
21 September 2020 - Proxy Form
21 September 2020 - Notice of Annual General Meeting
14 September 2020 - Appendix 3G - issue of options
2 September 2020 - Appendix 3G - issue of options
2 September 2020 - Initial Director's Interest Notice
1 September 2020 - Lapse of unlisted options
1 September 2020 - Final Director's Interest Notice
1 September 2020 - Director Appointment/Resignation
August
28 August 2020 - Appendix 4G and Corporate Governance Statement
26 August 2020 - Appendix 4E and Annual Report
12 August 2020 - Cleansing Notice and Appendix 2A
7 August 2020 - Change of Company Addresses
July
29 July 2020 - Business Update and Change to Board and Management
29 July 2020 - Activities Report and Appendix 4C June 2020 Quarter
13 July 2020 - Appointment of M Leydin as Chief Financial Officer
June
30 June 2020 - Invion subsidiary signs Supply Agreement with Pavay Biotech
23 June 2020 - Acceptance of New Zealand Patent Application
April
20 April 2020 - Program Update - March 2020 quarter
20 April 2020 - Appendix 4C - March 2020 quarter
15 April 2020 - Preliminary data links Photosoft with immune response
February
24 February 2020 - App 4D and Financial Report for half year to 31 Dec 2019
14 February 2020 - Photosoft data presented to Lorne Cancer Conference
5 February 2020 - Clarification to announcements of 3 February 2020
3 February 2020 - Lapse of unlisted share options
3 February 2020 - Invion signs R&D Services Agreement with Pavay Biotech
January
30 January 2020 - Appendix 4C December 2019 - cover note and market update
30 January 2020 - Appendix 4C - December 2019 quarter
9 January 2020 - App 3Z - Campbell - correction to date ceased to be director
December
24 December 2019 - MoU with Pavay on potential supply of dermatology compound
23 December 2019 - Final Directors Interest Notice - Campbell
23 December 2019 - Initial Directors Interest Notice - Farris
23 December 2019 - Change in Board and Management
November
29 November 2019 - Additional Information to Prior Announcement
27 November 2019 - Photosoft technology shrinks ovarian cancer in vivo
4 November 2019 - App 3X - Initial Directors Interest Notice - C Newton
4 November 2019 - App 3Z - Director's Final Interests Notice - G Collier
4 November 2019 - Results of AGM
4 November 2019 - App 3Y - Change of Directors Interest Notice - G Collier
4 November 2019 - Chairman's Address and CEO Presentation to Board
October
31 October 2019 - Appendix 3B - issue of options to incoming CEO
31 October 2019 - Pre-clinical research agreement with Peter MacCallum CC
29 October 2019 - Appendix 4C - September 2019 quarter
24 October 2019 - C Newton to commence as CEO - Material terms of appointment
3 October 2019 - AGM Notice of Meeting
September
30 September 2019 - Investor Update - September 2019
30 September 2019 - Invion optimises PDT therapy and laser for 2020 human trials
August
28 August 2019 - Corporate Governance Statement
28 August 2019 - Appendix 4G
28 August 2019 - Appendix 4E and Financial Report for year ended 30 June 2019
15 August 2019 - Change in substantial holding
July
22 July 2019 - COO Craig Newton to transition to Invion CEO
12 July 2019 - Appendix 4C - June quarter
May
28 May 2019 - Animal studies show IVX-P02 potential in metastatic cancers
April
18 April 2019 - Quarterly Update
18 April 2019 - Appendix 4C - March 2019 quarter
1 April 2019 - Response to ASX Price Query
February
28 February 2019 - Corporate update to support BD and investor meetings
28 February 2019 - Corporate Update and Investor Presentation - Q1 2019
26 February 2019 - Appendix 4D and Financial Report for Half Year to 31 Dec 18
21 February 2019 - Shareholder Q&A on spinout of Chronic Airway Therapeutics
21 February 2019 - Response to ASX Appendix 4C Query
18 February 2019 - App 3Y Change in Director Interests - T Chew
18 February 2019 - App 3Y Change in Director Interests - G Collier
18 February 2019 - App 3Y Change in Director Interests - J Campbell
18 February 2019 - App 3X Initial Directors Interest Notice - A Yamashita
18 February 2019 - App 3Z Final Directors Interest Notice - M Glass
12 February 2019 - Appendix 3B - issue of shares and unlisted share options
12 February 2019 - Invion completes spin-out of respiratory assets
January
30 January 2019 - General Meeting - Results of Meeting
30 January 2019 - CEO Update to General Meeting
29 January 2019 - Invion selects Guilin Xingda for light-therapy manufacture
29 January 2019 - Appendix 4C - December quarter
16 January 2019 - Invion appoints cancer experts to Scientific Advisory Board
December
24 December 2018 - Appendix 3Y - Change in Director Interests - Thian Chew
21 December 2018 - General Meeting - Notice of Meeting
21 December 2018 - Respiratory Assets Demerger - Receipt of draft Class Ruling
14 December 2018 - Appendix 3Y - Change in Director Interests - Thian Chew
November
29 November 2018 - Demerger of respiratory assets - update
19 November 2018 - Ceasing to have an interest over shares
19 November 2018 - Appendix 3B - lapse of unlisted share options
19 November 2018 - Notification regarding release of escrowed securities
16 November 2018 - Invion Constitution adopted 13 November 2018
13 November 2018 - Annual General Meeting - Results of Meeting
13 November 2018 - Chairman's Address and CEO Presentation to AGM
7 November 2018 - Invion collaborates to develop powerful skin cancer gel
October
29 October 2018 - Appendix 4C - September 2018 quarter
September
27 September 2018 - CAT appoints R&G Pharma as CRO for nadolol in China
25 September 2018 - New Photosoft formulation increased effect in ovarian cancer
24 September 2018 - AGM Notice of Meeting
10 September 2018 - Photosoft granted Australian patent and Business Update
7 September 2018 - Demerger - clarification on eligible shareholders
5 September 2018 - Spin out of respiratory assets for development in China
August
28 August 2018 - Highlights of financial and operating results for FY2018
28 August 2018 - Corporate Governance Statement
28 August 2018 - Appendix 4G - Key to Governance Disclosures
28 August 2018 - Appendix 4E Annual Report and Full Year Statutory Accounts
July
27 July 2018 - Appendix 4C - June 2018 quarter
5 July 2018 - Photosoft efficiently destroys ovarian cancer cells in vitro
May
29 May 2018 - Appendix 3B - shares issued upon exercise of options
22 May 2018 - Appendix 3B - shares issued on exercise of options
14 May 2018 - Appendix 3B - issue of shares following options exercise
10 May 2018 - Appendix 3B - issue of shares following options exercise
April
30 April 2018 - Shareholder Newsletter
30 April 2018 - Appendix 3B - issue of shares following options exercise
26 April 2018 - App 3B - issue of 10M shares following option exercise
26 April 2018 - Appendix 4C - March 2018 quarter
19 April 2018 - App 3B - issue of 2M shares following option exercise
18 April 2018 - Appendix 3Y - change to director interests Mitchell Glass
17 April 2018 - Appendix 3B - unlisted share options
March
29 March 2018 - Response to ASX Price Query
22 March 2018 - Final Director's Interest Notice
22 March 2018 - Change to Board of Invion - retirement of Mr Warren Brown
21 March 2018 - Appointment of Dr Andrew Stephens to Advisory Board
20 March 2018 - Invion alliance with Hudson Institute of Medical Research
19 March 2018 - Appendix 3Y - Chew
19 March 2018 - Appendix 3Y - Collier
19 March 2018 - Appendix 3Y - Campbell
19 March 2018 - Appendix 3Y - Brown
16 March 2018 - Change of Registered Address and Principal Place of Business
15 March 2018 - Appendix 3B - allotment of Rights Issue Shares
13 March 2018 - Completion of Rights Issue
1 March 2018 - Response to ASX Price Query
28 February 2018 - Appendix 4D and Financial Report for half year to 31 Dec 17
20 February 2018 - Notice of despatch of Rights Issue documentation
12 February 2018 - Rights Issue - Notice to option holders
12 February 2018 - Rights Issue - Notice to ineligible shareholders
12 February 2018 - Rights Issue - Notice to eligible shareholders
12 February 2018 - Appendix 3B - for quotation of Rights Issue shares
12 February 2018 - Rights Issue Information Booklet
12 February 2018 - Invion announces underwritten Right Issue
12 February 2018 - Corporate presentation - February 2018
12 February 2018 - Cleansing Notice - Rights Issue
8 February 2018 - Response to ASX Price Query
January
29 January 2018 - Appendix 4C - December 2017 Quarter
2 January 2018 - Notice of initial substantial holder- UIG Limited